Literature DB >> 21546580

cAMP-guanine exchange factor protection from bile acid-induced hepatocyte apoptosis involves glycogen synthase kinase regulation of c-Jun NH2-terminal kinase.

A Johnston1, K Ponzetti, M S Anwer, C R L Webster.   

Abstract

Cholestatic liver disorders are accompanied by the hepatic accumulation of cytotoxic bile acids that induce cell death. Increases in cAMP protect hepatocytes from bile acid-induced apoptosis by a cAMP-guanine exchange factor (cAMP-GEF)/phosphoinositide-3-kinase (PI3K)/Akt pathway. The aim of these studies was to identify the downstream substrate in this pathway and to determine at what level in the apoptotic cascade cytoprotection occurs. Since inhibitory phosphorylation of glycogen synthase kinase-3 (GSK) occurs downstream of PI3K/Akt and this phosphorylation has been implicated in cell survival, we conducted studies to determine whether GSK was downstream in cAMP-GEF/PI3K/Akt-mediated cytoprotection. Our results show that treatment of hepatocytes with the cAMP-GEF-specific analog, 4-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cAMP, results in PI3K-dependent phosphorylation of GSK. Direct chemical inhibition of GSK in rat hepatocytes or human HUH7-NTCP cells with several structurally and functionally distinct inhibitors including bromoindirubin-3'-oxime (BIO), maleimides (SB216763, SB415286), thiadiazolidine derivatives, and LiCl attenuates apoptosis induced by glycochenodeoxycholate (GCDC). In addition, genetic silencing of the GSK β isoform with small interfering RNA attenuates GCDC apoptosis in HUH7-NTCP cells. Adenoviral inhibition of the Rap1 blocks both cAMP-GEF-mediated cytoprotection against GCDC-induced apoptosis and Akt/GSK3β phosphorylation. GCDC-induced phosphorylation of the proapoptotic kinase, c-Jun NH(2)-terminal kinase (JNK) is inhibited by GSK inhibition or cAMP-GEF activation. GCDC-induced apoptosis is accompanied by phosphorylation of the endoplasmic reticulum stress markers pIEF2α and IRE-1, and pretreatment with the cAMP-GEF analog or GSK inhibitors prevents this phosphorylation. Collectively, our results support the presence of a cAMP/cAMP-GEF/Rap1/PI3K/Akt/GSKβ survival pathway in hepatocytes that inhibits bile acid-induced JNK phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546580      PMCID: PMC3280825          DOI: 10.1152/ajpgi.00430.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  97 in total

1.  Protein kinase B/Akt mediates cAMP- and cell swelling-stimulated Na+/taurocholate cotransport and Ntcp translocation.

Authors:  Cynthia R L Webster; Usha Srinivasulu; Meenakshisundaram Ananthanarayanan; Frederick J Suchy; M Sawkat Anwer
Journal:  J Biol Chem       Date:  2002-05-28       Impact factor: 5.157

2.  Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation.

Authors:  Ingrid M Nijholt; Amalia M Dolga; Anghelus Ostroveanu; Paul G M Luiten; Martina Schmidt; Ulrich L M Eisel
Journal:  Cell Signal       Date:  2008-05-16       Impact factor: 4.315

3.  Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling.

Authors:  Seung Namkoong; Chun-Ki Kim; Young-Lai Cho; Ji-Hee Kim; Hansoo Lee; Kwon-Soo Ha; Jongseon Choe; Pyeung-Hyeun Kim; Moo-Ho Won; Young-Geun Kwon; Eun Bo Shim; Young-Myeong Kim
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

Review 4.  GSK-3beta, a therapeutic target for cardiomyocyte protection.

Authors:  Tetsuji Miura; Takayuki Miki
Journal:  Circ J       Date:  2009-06-09       Impact factor: 2.993

5.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

6.  cAMP inhibits bile acid-induced apoptosis by blocking caspase activation and cytochrome c release.

Authors:  Cynthia R L Webster; Paul Usechak; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-09       Impact factor: 4.052

7.  Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.

Authors:  Yuzo Kodama; Kojiro Taura; Kouichi Miura; Bernd Schnabl; Yosuke Osawa; David A Brenner
Journal:  Gastroenterology       Date:  2009-01-06       Impact factor: 22.682

8.  Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.

Authors:  Daniel I Perez; Santiago Conde; Concepción Pérez; Carmen Gil; Diana Simon; Francisco Wandosell; Francisco J Moreno; José L Gelpí; Francisco J Luque; Ana Martínez
Journal:  Bioorg Med Chem       Date:  2009-08-22       Impact factor: 3.641

9.  cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 beta/alpha in rat hepatocytes.

Authors:  Anna Gates; Simon Hohenester; M Sawkat Anwer; Cynthia R L Webster
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02-05       Impact factor: 4.052

Review 10.  Glycogen synthase kinase 3: a key regulator of cellular fate.

Authors:  J E Forde; T C Dale
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

View more
  10 in total

1.  Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.

Authors:  Leila Gobejishvili; Shirish Barve; Katja Breitkopf-Heinlein; Yan Li; JingWen Zhang; Diana V Avila; Steven Dooley; Craig J McClain
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 3.  The Emerging Role of Soluble Adenylyl Cyclase in Primary Biliary Cholangitis.

Authors:  Jung-Chin Chang; Ulrich Beuers; Ronald P J Oude Elferink
Journal:  Dig Dis       Date:  2017-03-01       Impact factor: 2.404

4.  Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.

Authors:  Walter E Rodriguez; Banrida Wahlang; Yali Wang; Jingwen Zhang; Manicka V Vadhanam; Swati Joshi-Barve; Philip Bauer; Robert Cannon; Ali Reza Ahmadi; Zhaoli Sun; Andrew Cameron; Shirish Barve; Claudio Maldonado; Craig McClain; Leila Gobejishvili
Journal:  Hepatology       Date:  2019-06-25       Impact factor: 17.425

5.  Bile Acid Toxicity and Protein Kinases.

Authors:  Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

7.  Taurolithocholate-induced MRP2 retrieval involves MARCKS phosphorylation by protein kinase Cϵ in HUH-NTCP Cells.

Authors:  Christopher M Schonhoff; Cynthia R L Webster; M Sawkat Anwer
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

8.  Hydrophobic bile acid apoptosis is regulated by sphingosine-1-phosphate receptor 2 in rat hepatocytes and human hepatocellular carcinoma cells.

Authors:  Cynthia R L Webster; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-17       Impact factor: 4.052

9.  Mechanism of inhibition of taurolithocholate-induced retrieval of plasma membrane MRP2 by cyclic AMP and tauroursodeoxycholate.

Authors:  Se Won Park; Cynthia R L Webster; Mohammed S Anwer
Journal:  Physiol Rep       Date:  2017-12

Review 10.  How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma.

Authors:  Celia Sequera; Sara Manzano; Carmen Guerrero; Almudena Porras
Journal:  Hepat Oncol       Date:  2018-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.